PTG-007 is under clinical development by PolTREG and currently in Phase II for Relapsing Remitting Multiple Sclerosis (RRMS). According to GlobalData, Phase II drugs for Relapsing Remitting Multiple Sclerosis (RRMS) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PTG-007’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PTG-007 overview

PTG-007 is under development for the treatment of type 1 diabetes in children and RRMS, primary progressive multiple sclerosis. It comprises of T-regulatory autologous lymphocytes. It is administered through intravenous route.

PolTREG overview

PolTREG is a provider of biotechnology research and development services that develops therapies for autoimmune diseases using T-regulatory cells.It is headquartered in Gdansk, Poland.

For a complete picture of PTG-007’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.